- Home
- TCRX vs GLU Comparison
TCRX vs GLU Comparison
Compare TCRX & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- GLU
- Stock Information
- Founded
- TCRX 2018
- GLU 2004
- Country
- TCRX United States
- GLU United States
- Employees
- TCRX N/A
- GLU N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- GLU Finance/Investors Services
- Sector
- TCRX Health Care
- GLU Finance
- Exchange
- TCRX Nasdaq
- GLU Nasdaq
- Market Cap
- TCRX 90.5M
- GLU 94.0M
- IPO Year
- TCRX 2021
- GLU N/A
- Fundamental
- Price
- TCRX $1.27
- GLU $16.68
- Analyst Decision
- TCRX Strong Buy
- GLU
- Analyst Count
- TCRX 7
- GLU 0
- Target Price
- TCRX $9.86
- GLU N/A
- AVG Volume (30 Days)
- TCRX 389.5K
- GLU 12.4K
- Earning Date
- TCRX 05-06-2025
- GLU 01-01-0001
- Dividend Yield
- TCRX N/A
- GLU 8.60%
- EPS Growth
- TCRX N/A
- GLU N/A
- EPS
- TCRX N/A
- GLU 0.62
- Revenue
- TCRX $4,421,000.00
- GLU N/A
- Revenue This Year
- TCRX $47.30
- GLU N/A
- Revenue Next Year
- TCRX $74.30
- GLU N/A
- P/E Ratio
- TCRX N/A
- GLU $22.50
- Revenue Growth
- TCRX N/A
- GLU N/A
- 52 Week Low
- TCRX $1.02
- GLU $11.61
- 52 Week High
- TCRX $9.69
- GLU $15.40
- Technical
- Relative Strength Index (RSI)
- TCRX 37.62
- GLU 61.44
- Support Level
- TCRX $1.32
- GLU $16.42
- Resistance Level
- TCRX $1.65
- GLU $16.95
- Average True Range (ATR)
- TCRX 0.12
- GLU 0.45
- MACD
- TCRX -0.02
- GLU 0.07
- Stochastic Oscillator
- TCRX 0.00
- GLU 77.31
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.